These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9741208)

  • 1. [Hepatitis B virus and the inflammatory/immunologic response (II): a new opportunity for the treatment of chronic hepatitis B and a suggestion for the treatment of other persistent viral diseases].
    Villarrubia VG; Herrerías JM; Alvarez-Mon M; Chirigos MA
    Rev Esp Enferm Dig; 1998 Jul; 90(7):514-22. PubMed ID: 9741208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA; Quiroga JA; Subirá D; Castañón S; Esteban JM; Pardo M; Carreño V
    Hepatology; 2001 Jan; 33(1):295-300. PubMed ID: 11124848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hepatitis B virus (HBV) and the inflammatory/immune response. I. The natural environment of the antigen presentation and immunologic chaos induced by the virus].
    Villarrubia VG; Alvarez-Mon M; Chirigos MA; Herrerías JM
    Rev Esp Enferm Dig; 1997 Dec; 89(12):919-28. PubMed ID: 9494379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2.2.15 cell lines.
    Sun Y; Chen HY; Xin SJ
    Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):230-4. PubMed ID: 15138116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term treatment of chronic hepatitis B and the strategy of anti-virus treatment].
    Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):625. PubMed ID: 15504298
    [No Abstract]   [Full Text] [Related]  

  • 6. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity.
    Rigopoulou EI; Suri D; Chokshi S; Mullerova I; Rice S; Tedder RS; Williams R; Naoumov NV
    Hepatology; 2005 Nov; 42(5):1028-36. PubMed ID: 16250037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B: current challenges and future directions.
    Chin R; Locarnini S
    Rev Med Virol; 2003; 13(4):255-72. PubMed ID: 12820187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment.
    Feld JJ; Heathcote EJ
    Semin Liver Dis; 2006 May; 26(2):116-29. PubMed ID: 16673290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy of chronic hepatitis B.
    Zoulim F
    Antiviral Res; 2006 Sep; 71(2-3):206-15. PubMed ID: 16716414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.
    Hadziyannis SJ; Papatheodoridis GV
    Semin Liver Dis; 2006 May; 26(2):130-41. PubMed ID: 16673291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring immunity in viral hepatitis.
    Kanto T; Hayashi N
    J Gastroenterol; 2004 Aug; 39(8):709-16. PubMed ID: 15338363
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel treatment options for hepatitis B virus infection.
    Kumar R; Agrawal B
    Curr Opin Investig Drugs; 2004 Feb; 5(2):171-8. PubMed ID: 15043391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study.
    Yang SH; Lee CG; Park SH; Im SJ; Kim YM; Son JM; Wang JS; Yoon SK; Song MK; Ambrozaitis A; Kharchenko N; Yun YD; Kim CM; Kim CY; Lee SH; Kim BM; Kim WB; Sung YC
    Gene Ther; 2006 Jul; 13(14):1110-7. PubMed ID: 16525482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F
    Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model.
    Roggendorf M; Schulte I; Xu Y; Lu M
    J Viral Hepat; 2007 Nov; 14 Suppl 1():51-7. PubMed ID: 17958643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.